The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics

Shanghai Jiao Tong University

Status: Not yet enrolling

Conditions: Sodium-glucose Co-transporter-2 Inhibitor; Myocardial Fibrosis; Obesity; Type 2 Diabetes; Magnetic Resonance Imaging

Treatments: Drug: Henagliflozin; Drug: Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT06059287

IIT-2023-0180

Details and patient eligibility

About

This is a prospective, randomized, open-label, active drug controlled clinical trial that aims to compare the effects of henagliflozin or metformin on myocardial tissue level characteristics in type 2 diabetes patients with obesity. Eligible subjects with type 2 diabetes before randomisation and fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1 ratio to henagliflozin 10 mg once a day or metformin 1000 mg twice a day and treated for 24 weeks. The study includes five visits.

Full description

MRI scanning will be assessed at baseline and at the end of the treatment period in order to to assess the cardiac morphology, cardiac function, and myocardial tissue characteristics. The cardiac MRI examination will be performed in accordance with a pre-defined MRI protocol. Images from all sites will be analyzed centrally at the core-lab using a dedicated software package and certified analysts.

Enrollment: 64 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals with type 2 diabetes newly diagnosed based on the WHO (1999) criteria;
• Hemoglobin A1c levels >=7.0% and <=8.0%;
• Females or males ≥18 years up to 75 years of age.

Exclusion criteria

• Females or males <18 years.

• Clinical diagnosis of type 1 diabetes and other types of diabetes.

• Blood pressure at screening that would require a change in blood pressure treatment over the study period.

• History of stroke or other clinically significant cerebrovascular disease.

• Any of the following cardiovascular diseases:

  1. Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function
  2. Unstable heart failure or any heart failure with NYHA class III and IV
  3. Significant valvular disease
  4. Significant peripheral artery disease

• Active malignancy requiring treatment at the time of visit 0.

• Patients with severe hepatic impairment.

• Unstable or rapidly progressing renal disease.

• Ongoing treatment with loop diuretics.

• Estimated Glomerular Filtration Rate (eGFR) <45 mL/min/1.73 m2.

• Women who has a positive pregnancy test at enrolment or randomization, or are breastfeeding.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

64 participants in 2 patient groups

Henagliflozin

Experimental group

Description:

Henagliflozin 10mg qd po

Treatment:

Drug: Henagliflozin

Metformin

Active Comparator group

Description:

Metformin 1000mg bid po

Treatment:

Drug: Metformin